INTRODUCTION
Helicobacter pylori (H. pylori) is one of the most common causes of chronic bacterial infection in humans: it is thought that nearly one-half of the entire world population has been infected by H. pylori. 1 In addition, H. pylori is widely known to be related to chronic gastritis, peptic ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Therefore, the International Agency for Research on Cancer, a branch of the World Health Organization, categorizes H. pylori as a definite gastric carcinogen (group I). 2 The eradication of H. pylori is a serious issue for improving public health. However, the efficacy of first-line clarithromycincontaining triple therapy, which is generally composed of proton pump inhibitor (PPI), amoxicillin, and clarithromycin, is consistently declining worldwide. 3 This tendency is similar in Korea, and the eradication rates of H. pylori using clarithromycin-containing triple therapy, reported at 84.9-87.5% from 2001 to 2007 and 80.0-81.4% from 2008 to 2010 (p<0.0001), have shown a decreasing trend over the past 10 years in Korea. 4 Thus, a potent second-line regimen is required for successful H. pylori eradication.
There are several guidelines for H. pylori eradication in the East and the West, and various regimens are recommended for second-line therapy. Bismuth-containing quadruple therapy, usually consisting of bismuth, tetracycline, metronidazole, and PPI, is recommended in Korea 5 and China. 6 However, metronidazole-containing triple therapy, which is composed of amoxicillin, metronidazole, and PPI, is recommended in Japan. 7 According to Western guidelines, the Maastricht V/Florence consensus report recommended a bismuth-containing quadruple therapy or a fluoroquinolone-containing triple therapy for second-line therapy for H. pylori eradication in patients who failed clarithromycin-containing triple therapy. 8 Several studies evaluated the H. pylori eradication rates between bismuth-containing quadruple therapy and fluoroquinolone-containing triple therapy; however, the results are conflicting. [9] [10] [11] [12] From this background, the aims of this study are to investigate the efficacy, compliance, and adverse effects of 14-day moxifloxacin-containing triple therapy in second-line H. pylori eradication compared with 7-day bismuth-containing quadruple therapy.
SUBJECTS AND METHODS

Study population
Patients who failed first-line 7-day clarithromycin-containing triple therapy (standard-dose PPI, 1.0 g amoxicillin, and 0.5 g clarithromycin, twice daily) and who received second-line H. rabeprazole twice daily, 300 mg of tripotassium dicitrato bismuthate, 500 mg of metronidazole three times daily, and 500 mg of tetracycline four times daily for 7 days (7-RBMT).
Moxifloxacin-containing triple therapy was comprised of 40 mg of esomeprazole twice daily, 1.0 g of amoxicillin twice daily, and 400 mg of moxifloxacin once daily for 14 days (14-EAM). 
13 C-urea breath test (UBiT-IR300 ® )
Prior to collection of the first breath sample, patients fasted for at least 4 hours. Afterwards, patients took 100 mg tablets of 13 C-urea (UBiTkit TM , Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) with 100 mL of water orally, and the second breath sample was collected 20 minutes after taking the tablets.
The obtained breath samples were analyzed using the 13 C-urea breath test (UBiT-IR300 ® ). The cut-off value in the procedure was set at 2.5‰. 
Statistical analyses
RESULTS
Patient characteristics
Between January 2011 to December 2015, 569 patients failed the first-line clarithromycin-containing triple therapy.
Initially, 487 patients received 7-RBMT and 82 patients received 14-EAM for second-line eradication therapy. In the 7-RBMT group, 94 patients (19.3%) were lost to follow-up and two patients (0.4%) were excluded due to poor compliance.
In the 14-EAM group, 13 patients (15.9%) were lost to follow-up and four patients (4.9%) were excluded due to poor compliance. Therefore, 391 patients in the 7-RBMT group and 65 patients in the 14-EAM group were included as subjects for PP analysis (Fig. 1 ). p=0.005) ( Table 2 ).
H. pylori eradication rates
Adverse effects of eradication therapy
Adverse effects were recorded in 67 patients (17.1%) in the 7-RBMT group and five patients (7.7%) in the 14 Table 3) . 
Related factors for eradication failure
DISCUSSION
Bismuth-containing quadruple therapy is a widely used second-line H. pylori eradication therapy, but moxifloxacin-containing triple therapy has been suggested as an alternative second-line therapy for H. pylori infection. 8, 12, 13 A meta-analysis study reported that moxifloxacin-containing triple therapy was more effective than bismuth-containing quadruple therapy in the second-line eradication of H. pylori. 12 However, a recent study in Korea revealed that 7-RBMT has remained efficacious as a second-line regimen over the last 10 years, and there have been no significant changes in eradication rates with time (eradication rate range: 83.2-93.7%, p=0.352). 4 In addition, the eradication rates of 14-day moxifloxacin-containing triple therapy range from 82.8-98.1%, which are similar to those of bismuth-containing quadruple therapy. 14 Several studies have investigated the effects of second-line H. pylori eradication therapies, including bismuth-containing quadruple therapy and moxifloxacin-containing triple therapy. 12 However, to the best of our knowledge, this is the first study to directly compare 7-day bismuth-containing quadruple therapy and 14-day moxifloxacin-containing triple therapy.
Generally, well-known correlating factors of H. pylori eradication failure include resistance to antibiotic agents and poor patient compliance with regard to medication. 15 In the case of first-line triple therapy, clarithromycin resistance is a critical 32 김성은 등. 헬리코박터 이차 치료로써 Bismuth 포함 사제 요법
The Korean Journal of Gastroenterology determinant for eradication success. For bismuth-containing quadruple therapy, metronidazole resistance is considered an important factor for deciding the success of eradication, 16 because resistance to tetracycline is low in the most countries. 17, 18 Even in Korea where the antibiotic resistance rate of H. pylori is high, the resistance rate to tetracycline was reported to be similar for the past 11 years (p=0.761), 19 whereas the rate of metronidazole resistance is usually 20-40% in Western countries and 50-80% in developing countries. 20 A recent study in Korea demonstrated that the resistance rate of metronidazole was stable from 2003-2012 (p=0.418) with a prevalence of 26.0-35.8%. 21 Resistance to fluoroquinolones also affects the H. pylori eradication rate, and, unfortunately, the prevalence of fluoroquinolone resistance is rapidly increasing worldwide. 16 A recent study reported a high rate of resistance to levofloxacin (53.01%), moxifloxacin (46.57%), and ciprofloxacin (44.28%) in Italy. 22 Lee et al. 21 also revealed the prevalence of levofloxacin (34.6%) and moxifloxacin (34.6%) resistance in Korea, and showed that the resistance rates of levofloxacin (p<0.001) and moxifloxacin (p<0.001) significantly increased over the past 10 years. When they analyzed the data by the primary and secondary resistance, a statistically significant increase was shown in the secondary resistance rate to moxifloxacin (p=0.025); the prevalence of secondary moxifloxacin resistance was 50.0% from 2009 to 2012.
In the current study, the H. pylori eradication failure rate associated with 14-EAM was significantly higher than that associated with 7-RBMT; the OR was 5.47 (p<0.001 With regard to the treatment duration, the shorter treatment duration seen with bismuth-containing quadruple therapy was more effective than the longer treatment duration associated with moxifloxacin-containing triple therapy in this study.
Treatment duration of bismuth-containing quadruple therapy
is an important factor in eradication success when the traditional bismuth-containing quadruple therapy is prescribed. 24 It is known that metronidazole resistance could be overcome by prolongation of treatment duration. 25 A meta-analysis study revealed that bismuth-containing quadruple therapy for 10-14 days was more efficient than when it was given for either 1-3 days, 4 days, or 7 days. 26 However, this is thought to be applicable only to first-line H. pylori quadruple eradication therapies. In patients who are non-naïve to H. pylori eradication therapy, namely, those who failed first-line eradication therapy, the 7-day treatment duration of bismuth-containing quadruple therapy seemed sufficient. 23 Several studies reported that the eradication rates of second-line bismuth-containing quadruple therapy were similar in patients with treatment durations of 7, 10, and 14 days. 27, 28 A recent randomized controlled trial in Korea also reported that the 7-day second-line bismuth-containing quadruple therapy was not statistically inferior to the 14-day bismuth-containing quadruple therapy. 29 Even if 7-day bismuth-containing quadruple therapy showed unacceptable eradication rates in areas where antibiotic resistance to metronidazole is ≥40%, 24 more studies are required to investigate the efficacy, cost, safety, and ideal duration of bismuth-containing quadruple therapy as a second-line eradication therapy.
Although there was no statistical difference, the rate of adverse effects in the 7-RBMT group tended to be higher than that of the 14-EAM group in this study. A meta-analysis reported that the rate of side effects associated with moxifloxacin-containing triple therapy was statistically lower than that of bismuth-containing quadruple therapy (OR, 0.27; 95% CI, 0.18-0.4). 12 Recently, a single capsule with a composite of bismuth, metronidazole, and tetracycline has been developed to make the bismuth-containing quadruple therapy simpler for patients, and the results of studies of this new medication, including eradication rate, compliance, and safety profiles, were inspiring. 30, 31 Therefore, the compliance and adverse effect rates of bismuth-containing quadruple therapy is expected to improve in the future.
This study has several limitations. First, many patients in the present study were lost to follow-up. In addition, there was a large difference in the number of patients between the two group. These could affect the results as bias. Second, we did not investigate cytochrome P450 2C19 (CYP2C19) me- tabolism, which induces many drug metabolism pathways, including that for PPI. Therefore, a disparity in CYP2C19 genotypes can influence the eradication rate. In addition, the rates of cigarette smoking and alcohol intake were higher in the 14-EAM group compared to the 7-RBMT group. In previous studies, several factors have been presumed to be the cause of eradication failure, including age, sex, smoking, alcohol, and diabetes. [32] [33] [34] [35] However, a direct relationship between these factors and eradication failure remains controversial. [32] [33] [34] [35] Therefore, it is uncertain but unlikely that these factors could have had a significant influence on the current study.
In conclusion, compared to 14-day moxifloxacin-containing triple therapy, 7-day bismuth-containing quadruple therapy might provide benefits for patients who failed first-line triple therapy. In addition, the present study suggests that the poor compliance and high adverse event rates associated with bismuth-containing quadruple therapy could be overcome by its relative short duration for eradication therapy. Additional well-designed, prospective, large-scale studies are required to confirm the appropriate second-line therapy for H. pylori eradication.
